43 related articles for article (PubMed ID: 11481375)
1. A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment.
Taube SE; Clark GM; Dancey JE; McShane LM; Sigman CC; Gutman SI
J Natl Cancer Inst; 2009 Nov; 101(21):1453-63. PubMed ID: 19855077
[TBL] [Abstract][Full Text] [Related]
2. Differential Expression of RAGE, EGFR and Ki-67 in Primary Tumors and Lymph Node Deposits of Breast Carcinoma.
Aboushousha T; Hammam O; Safwat G; Eesa A; Ahmed S; Esmat ME; Helmy AH
Asian Pac J Cancer Prev; 2018 Aug; 19(8):2269-2277. PubMed ID: 30139236
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Her-2, EGFR and cyclin D1 in primary breast cancer and paired metastatic lymph nodes: an immunohistochemical and chromogenic in situ hybridization study.
Cho EY; Han JJ; Choi YL; Kim KM; Oh YL
J Korean Med Sci; 2008 Dec; 23(6):1053-61. PubMed ID: 19119452
[TBL] [Abstract][Full Text] [Related]
4. HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review.
Carlsson J; Nordgren H; Sjöström J; Wester K; Villman K; Bengtsson NO; Ostenstad B; Lundqvist H; Blomqvist C
Br J Cancer; 2004 Jun; 90(12):2344-8. PubMed ID: 15150568
[TBL] [Abstract][Full Text] [Related]
5. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer.
Simon R; Nocito A; Hübscher T; Bucher C; Torhorst J; Schraml P; Bubendorf L; Mihatsch MM; Moch H; Wilber K; Schötzau A; Kononen J; Sauter G
J Natl Cancer Inst; 2001 Aug; 93(15):1141-6. PubMed ID: 11481385
[TBL] [Abstract][Full Text] [Related]
6. Fluorescence in situ hybridization for HER-2/neu amplification of breast carcinoma in archival fine needle aspiration biopsy specimens.
Gu M; Ghafari S; Zhao M
Acta Cytol; 2005; 49(5):471-6. PubMed ID: 16334021
[TBL] [Abstract][Full Text] [Related]
7. HER-2 status determination in breast carcinomas. A practical approach.
García-Caballero T; Menéndez MD; Vázquez-Boquete A; Gallego R; Forteza J; Fraga M
Histol Histopathol; 2006 Mar; 21(3):227-36. PubMed ID: 16372244
[TBL] [Abstract][Full Text] [Related]
8. Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer.
Sassen A; Diermeier-Daucher S; Sieben M; Ortmann O; Hofstaedter F; Schwarz S; Brockhoff G
Breast Cancer Res; 2009; 11(4):R50. PubMed ID: 19624808
[TBL] [Abstract][Full Text] [Related]
9. Are patterns of HER-2/neu amplification and expression among primary tumors and regional metastases indicative of those in distant metastases and predictive of Herceptin response?
Thor A
J Natl Cancer Inst; 2001 Aug; 93(15):1120-1. PubMed ID: 11481375
[No Abstract] [Full Text] [Related]
10. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies.
Singer CF; Köstler WJ; Hudelist G
Biochim Biophys Acta; 2008 Dec; 1786(2):105-13. PubMed ID: 18375208
[TBL] [Abstract][Full Text] [Related]
11. HER2 status in breast cancer--an example of pharmacogenetic testing.
Kroese M; Zimmern RL; Pinder SE
J R Soc Med; 2007 Jul; 100(7):326-9. PubMed ID: 17606754
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
